The Company has experienced net losses and negative cash flows from operations
each period since its inception. Through
The Company has been engaged in developing LYPDISO (formerly MAT9001) as well as
its lipid nanocrystal ("LNC") platform delivery technology and a pipeline of
associated product candidates, including MAT2203 and MAT2501, since 2011. To
date, the Company has not obtained regulatory approval for any of its product
candidates nor generated any revenue from product sales, and the Company expects
to incur significant expenses to complete development of its product candidates.
The Company may never be able to obtain regulatory approval for the marketing of
any of its product candidates in any indication in
If the Company obtains
As of
Note 3 - Summary of Significant Accounting Policies
Basis of presentation and principles of consolidation
The accompanying unaudited condensed consolidated financial statements include
the consolidated accounts of Holdings and its wholly owned subsidiaries,
The Company's significant accounting policies are described in Note 3 within the Company's Notes to Consolidated Financial Statements included in the Company's 2021 Form 10-K.
The Company's management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company's financial statements.
COVID-19
Since its emergence in 2019, COVID-19 has continued to spread and has adversely affected workforces, economies, and financial markets globally, and has and may continue to cause economic downturns.
5
The financial results for the three months ended
Note 4 - Cash, Cash Equivalents,
The Company considers all highly liquid financial instruments with original
maturities of three months or less when purchased to be cash and cash
equivalents and all investments with maturities of greater than three months
from date of purchase are classified as marketable securities. Cash and cash
equivalents consisted of cash in bank checking and savings accounts, money
market funds and short-term
Cash, Cash Equivalents and Restricted Cash
The Company presents restricted cash with cash and cash equivalents in the
Condensed Consolidated Statements of Cash Flows. Restricted cash at both
The following table provides a reconciliation of cash, cash equivalents and
restricted cash reported in the Condensed Consolidated Balance Sheets to the
total of the amounts in the Condensed Consolidated Statements of Cash Flows as
of
Schedule of Cash, Cash Equivalents and Restricted Cash
© Edgar Online, source